Mast-Cell Stabilizing Effects of Olopatadine

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00389025

Enrollment

Registered

2006-10-17

Start date

2006-10-31

Completion date

Unknown

Last updated

2016-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Keywords

Subject with clinical history of seasonal allergic conjunctivitis

Brief summary

To assess the effects of olopatadine of the release of mast cell histamine

Interventions

DRUGOlopatadine (generic name)

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Asymptomatic and not using any topical or systemic medication

Exclusion criteria

* Age

Design outcomes

Primary

Measure	Time frame
Tear histamine	—

Secondary

Measure	Time frame
Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness	—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026